Bone Cancer (Fact Sheet)
This fact sheet reviews bone cancer, including its possible causes, frequency, symptoms, diagnosis, and treatment.
Bone Cancer
Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
This phase 2 study sought to determine whether concurrent pantoprazole would improve cisplatin-induced ototoxicity and nephrotoxicity in younger patients with osteosarcoma.
Defects in DNA Imprinting Affect Development and Progression of Childhood Osteosarcoma
Osteosarcoma in children may be impacted by a defect in DNA imprinting that also occurs in their biological parents. These imprinting defects may be predictive of survival outcomes.
Potential treatment option discovered for children with Ewing’s sarcoma
Combining two anti-tumor agents appears to increase the sensitivity of cancer cells to these drugs and seems to lead to more effective Ewing’s sarcoma treatment.
Patients with rare bone cancer still have low survival rates
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types.
Zoledronic acid (Zometa)
This slideshow reviews zoledronic acid (Zometa), indicated for pain reduction associated with bone metastases, hypercalcemia of malignancy, and osteolytic lesions of multiple myeloma.
Potential therapeutic strategy against a very aggressive children’s bone cancer
Inhibiting the protein Sirtuin1 could play a part in fighting Ewing sarcoma, a common bone cancer in adolescents and children.
Single genetic abnormality important in Ewing sarcoma
Better understanding of the two distinct processes at the heart of the genetic abnormality driving Ewing sarcoma development could lead to new, more effective therapies.
PRM-151 therapy well tolerated by patients with advanced myelofibrosis
The compound PRM-151 (PRM) has shown success in reducing progressive bone marrow fibrosis in patients with advanced myelofibrosis.
Bone Cancer Treatment Regimens
Find the right bone cancer treatment regimen with detailed instructions on selection, dosing, and administration of anti-cancer agents such as vincristine.
